Clinical Trial Update: Romiplostim, Rituximab and Dexamethasone as Frontline Treatment for Immune Thrombocytopenia [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating romiplostim, rituximab, and dexamethasone as frontline treatment for immune thrombocytopenia and thrombotic thrombocytopenic purpura.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immune Thrombocytopenia
• Thrombotic Thrombocytopenic Purpura

Drugs mentioned

• DEXAMETHASONE (Dexamethasone)
• Rituximab (rituximab)
• Romiplostim (romiplostim)

Snippet

Sponsor: David Gomez Almaguer | Conditions: Immune Thrombocytopenia, Thrombotic Thrombocytopenic Purpura | Phase 2 | Status: UNKNOWN